Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts
for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

On November 11, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, reported that data from its AIPAC, TACTI-002 and TACTI-003 studies have been published in abstracts available via the links below on the SITC (Free SITC Whitepaper) 2021 Annual Meeting’s official website or the Company’s website (Press release, Immutep, NOV 11, 2021, View Source [SID1234595396]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Three poster presentations with additional data and commentary that are not included in the abstracts will be available on View Source from 12 November 2021, at 7 am EST and made available on Immutep’s website at www.immutep.com.

TACTI-002
Title: Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC).
Abstract: View Source
TACTI-003
Title: A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC).
Abstract: View Source
AIPAC
Note: A separate announcement detailing the AIPAC results has also been released today.
Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000

ABN: 90 009 237 889

Title: Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC.
Abstract: View Source
Webcast Details
Immutep will present the AIPAC data in a global webcast for investors. Details are as follows:
Date & Time 8.00 am AEDT (Sydney) Wednesday 17 November 2021
4.00 pm EST (New York) Tuesday 16 November 2021
10.00 pm CET (Berlin) Tuesday 16 November 2021
Register: View Source
Questions: Investors are invited to submit questions in advance via [email protected].